Adverse event (AE) reporting is one of the most critical responsibilities across the pharmaceutical industry. At its core, pharmacovigilance (PV) exists to protect patient safety and maintain regulatory compliance. Yet the success of any PV program depends heavily on accurate, timely AE identification, often before PV is ever involved.
This is where Medical Information (MI) plays a pivotal role.
MI teams are frequently the first point of contact for healthcare professionals and patients, receiving inquiries through calls, emails, and digital channels. Every interaction represents not only a request for scientific information, but also an opportunity to identify potential safety events that must be triaged appropriately. When MI and PV are well aligned, organizations strengthen both compliance and patient safety. When they are not, gaps emerge.
The Role of Medical Information: A Critical Front-Line Intake Channel
Medical Information functions as a front-line intake channel across multiple touchpoints, including:
- Inbound phone calls
- Written correspondence (email, webforms, fax)
- Digital and omnichannel platforms
Because of this direct access, MI teams are uniquely positioned to:
- Recognize potential adverse events, even when they are not explicitly stated
- Capture the minimum required safety details in line with regulatory expectations
- Triage identified AEs quickly and consistently to PV teams
Timeliness is as critical as accurate identification. Regulatory requirements impose strict reporting timelines for adverse events, with many requiring triaging to pharmacovigilance within one working day of initial awareness. Medical Information teams therefore play a key role in ensuring that all identified adverse events are transferred to the PV case processing team promptly and with complete and accurate information. Delays or incomplete handoffs can compromise reporting timelines and increase compliance risk, underscoring the importance of clearly defined processes, training, and close coordination between MI and PV.
At ProPharma, AE identification and reporting expectations are clearly defined through annual AE training and standardized SOPs. Client-specific nuances are then outlined in working practices (WPs), ensuring compliance while maintaining operational consistency across programs.
This structure is essential. Without a shared foundation and clear triage pathways, even experienced teams can struggle with consistent AE identification, particularly as volumes increase and engagement channels expand.
Where Gaps Commonly Occur
Despite well-intended processes, gaps in AE management still occur across the industry. Some of the most common challenges include:
- Inconsistent AE identification due to varying interpretations
- Process variability leading to delays or incomplete documentation
- Limited MI–PV coordination
PV teams often do not have direct access to MI databases or inquiry systems. As a result:
- Reconciliation between MI-identified AEs and PV case intake can be challenging
- PV may have limited visibility into how safety information is initially captured
Additionally, during field engagements, healthcare sales representatives and MSLs may not always recognize safety-relevant information or appropriately report it. MI teams frequently identify these events later through medical inquiry handling, acting as a critical safety net.
Why This Is Becoming More Complex
The AE landscape continues to evolve rapidly.
Increased Digital and Omnichannel Engagement
Today’s interactions extend beyond traditional phone calls. Patients and HCPs now engage through multiple digital channels, increasing both the volume and complexity of safety data intake.
Greater Regulatory Scrutiny
Health authorities expect robust documentation, traceability, and consistent reporting, regardless of the channel through which safety information is received.
Growing Need for MI–PV Alignment
Medical Information increasingly serves as a source of real-world insights and frontline patient experience. Because PV teams rarely speak directly with patients, MI plays a unique role in capturing lived experiences that may signal safety concerns.
Technology and AI: A Supportive Role, Not a Replacement
Across the industry, technology is being leveraged to address human variability in AE identification. Modern systems increasingly incorporate:
- Call transcripts and text analytics
- Keyword and phrase recognition to flag potential AEs
- Integrated workflows that improve MI and PV visibility
While these tools can significantly support intake and triage, they do not replace trained professionals. In regulated GxP environments, human oversight remains essential to apply professional judgment and ensure compliance.
Many organizations seek external support not due to a lack of technology, but because internal processes struggle with scale, consistency, or integration.
Industry Best Practices for Strengthening AE Identification
Organizations can strengthen AE capture and reporting by:
- Standardizing intake workflows across MI channels
- Aligning MI and PV processes with clear triage pathways
- Conducting regular training and refresher programs
- Monitoring quality metrics, reconciliation outcomes, and trends
- Leveraging technology thoughtfully and transparently
These practices help reduce risk while reinforcing patient safety as a shared responsibility.
Medical Information as a Key Control Point
AE reporting does not sit solely within pharmacovigilance. Medical Information operates at the intersection of patient engagement, scientific exchange, and regulatory obligation.
When MI teams are empowered with aligned processes, consistent training, and strong coordination with PV, they become more than an information resource. They become a foundational safeguard for compliance and patient safety.
In an increasingly complex regulatory environment, recognizing and strengthening the role of Medical Information in AE identification is not only best practice, but essential.
Author
TAGS: Medical Information Pharmacovigilance Adverse Events (AE)
